See more : Taiwan Cogeneration Corporation (8926.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Protara Therapeutics, Inc. (TARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Penyao Environmental Protection Co., Ltd. (300664.SZ) Income Statement Analysis – Financial Results
- EDP – Energias de Portugal, S.A. (EDP.LS) Income Statement Analysis – Financial Results
- Empresa Distribuidora y Comercializadora Norte Sociedad Anónima (EDN.BA) Income Statement Analysis – Financial Results
- Daan Gene Co., Ltd. (002030.SZ) Income Statement Analysis – Financial Results
- Unet Credit Finance Services Ltd (UNCR.TA) Income Statement Analysis – Financial Results
Protara Therapeutics, Inc. (TARA)
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.95M | 0.00 | 0.00 |
| Cost of Revenue | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 0.00 | 27.00K | 57.00K |
| Gross Profit | -341.00K | -247.00K | -1.17M | -196.00K | -16.00K | -115.00K | -148.00K | -123.00K | -57.00K | 2.95M | -27.00K | -57.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.99M | 16.81M | 21.09M | 11.98M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
| General & Administrative | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 105.99K | 9.84M | 8.49M | 4.10M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.42M | -123.00K | -57.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.10M | 3.10M | 2.03M |
| Other Expenses | 0.00 | 29.52M | 0.00 | 0.00 | 0.00 | 207.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.10M | 7.94M |
| Cost & Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.36M | 28.71M | 20.87M | 10.53M | 7.12M | 8.00M |
| Interest Income | 2.73M | 1.11M | 237.00K | 466.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 20.00K |
| Interest Expense | 0.00 | 1.14M | 1.74M | 34.00K | 0.00 | 0.00 | 259.00K | 193.00K | 144.00K | 857.00K | 861.00K | 0.00 |
| Depreciation & Amortization | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 30.00K | 27.00K | 57.00K |
| EBITDA | -43.27M | -64.57M | -46.09M | -33.78M | -7.81M | -20.61M | -29.82M | -28.40M | -21.32M | -2.45M | -7.02M | -7.91M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -83.28% | 0.00% | 0.00% |
| Operating Income | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.71M | -20.87M | -7.58M | -7.12M | -8.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -257.12% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.19M | 1.11M | 237.00K | 466.00K | 0.00 | 643.00K | 398.00K | 179.00K | -507.00K | 4.24M | -790.00K | 26.00K |
| Income Before Tax | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -117.00K | -466.00K | -262.00K | 5.35M | 657.00K | 372.00K | -363.00K | 5.10M | 0.00 | 0.00 |
| Net Income | -40.42M | -64.82M | -47.14M | -33.51M | -14.73M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| EPS | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| EPS Diluted | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| Weighted Avg Shares Out | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
| Weighted Avg Shares Out (Dil) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2023 and provided...
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating...
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
Dosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 Dosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected...
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment...
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2023 and provided...
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare...
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.
Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More
The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.
Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Source: https://incomestatements.info
Category: Stock Reports